Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications from Black Rock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 9 and 12 December 2019 respectively.
In the first notification, BlackRock, Inc., has notified that, following a disposal of UCB shares with voting rights by its affiliates, its holding of UCB shares with voting rights has decreased and has crossed downwards the 5% threshold on 6 December 2019.
On 6 December 2019, BlackRock, Inc. (taking into account the holding of its affiliates) Inc. owned 9 639 270 UCB shares with voting rights (versus 9 753 879 shares in its previous notification), representing 4.96% of the total number of shares issued by the company (194 505 658) (versus 5.01% in its previous notification), as well as 231 644 equivalent financial instruments (versus 216 713 in its previous notification) representing 0.12% of the total number of shares issued by the company (versus 0.11% in its previous notification).
In the second notification, BlackRock, Inc., has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its holding of UCB shares with voting rights has increased and has crossed the 5% threshold on 11 December 2019.
On 11 December 2019, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 735 421 UCB shares with voting rights, representing 5.01% of the total number of shares issued by the company, as well as 198 312 equivalent financial instruments, representing 0.10% of the total number of shares issued by the company.
Further information
This press release and the detailed transparency notifications are available on UCB SA/NV's website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.
Contact:
Antje Witte
Tel: +32.2.559.94.14
Email: antje.witte@ucb.com
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of EUR 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB).
(C) 2019 Electronic News Publishing, source ENP Newswire
UCB 
